iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning iRhythm business and prospects, resulting in its stock trading at inflated prices.

IRTC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that iRhythm Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead the iRhythm Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of iRhythm Technologies, Inc. (NASDAQ: IRTC) between January 11, 2022 and May 30, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024. SO WHAT: If you purchased iRhythm securities during the Cl.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages iRhythm Technologies, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – IRTC

NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit in the U.S. District Court for the Northern District of California alleging violations of the federal securities laws by iRhythm Technologies, Inc. (“iRhythm” or the “Company”) and certain of the Company's current and former senior executives (collectively, “Defendants”). The action is brought on behalf of all persons or entities that purc.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Amylyx Pharmaceuticals

Boston Scientific

CRISPR Therapeutics

Globus Medical

Moderna

Teladoc

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.

7 Healthcare Stocks Taking Medicine to the Next Level

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 42nd Annual J.P. Morgan Healthcare Conference.

iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference

Findings published in the American Heart Journal show higher clinical diagnostic yield and lower odds of retesting with Zio long-term continuous monitoring service (LTCM) compared to other LTCM and ambulatory cardiac monitoring (ACM) products LTCM was associated with lower incremental health care utilization and cost SAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) today announced that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events (CAMELOT) study have been published in the American Heart Journal (AHJ). The peer-reviewed manuscript, titled “Comparative Effectiveness and Healthcare Utilization for Ambulatory Cardiac Monitoring (ACM) Strategies in Medicare Beneficiaries,” reveals that the Zio long-term continuous monitoring service (LTCM), which features up to 14 continuous days of monitoring, was independently associated with the highest yield of clinical arrhythmia encounter diagnosis and lowest likelihood of retest.

Largest Ever Real-World Evidence Study of Ambulatory Cardiac Monitoring Demonstrates Clinical Superiority of iRhythm's Zio Long-Term Continuous Monitoring Service

SAN FRANCISCO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

iRhythm Technologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Axonics ModulationTechnologies Inc

Cava Group, Inc.

Goldman Sachs Small Cap Core Equity ETF

Meritage Homes

Novo Nordisk

Sweetgreen

Shake Shack

Tenable Holdings Inc

Wingstop

Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which has been the case for funds that track the S&P 500.

Goldman Sachs money manager digs into three themes for long-term growth

Study findings from a collaboration with Duke Health found that a model that incorporates ECG data from long-term continuous monitoring resulted in more accurate prediction of heart failure hospitalization compared to clinical risk models Study findings from a collaboration with Duke Health found that a model that incorporates ECG data from long-term continuous monitoring resulted in more accurate prediction of heart failure hospitalization compared to clinical risk models

New Research Presented at American Heart Association's 2023 Scientific Sessions Demonstrates Performance of Continuous Monitoring ECG Data for Improved Prediction of Heart Failure Hospitalization

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President & Chief Executive Officer Brice Bobzien - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Malgorzata Kaczor - William Blair David Saxon - Needham Nathan Treybeck - Wells Fargo John Young - Canaccord David Rescott - Baird Suraj Kalia - Oppenheimer Operator Hello and welcome to the iRhythm Technologies Inc. Q3 2023 Earnings Conference Call. My name is Alex, I'll be coordinating the call today.

iRhythm Technologies, Inc. (IRTC) Q3 2023 Earnings Call Transcript

SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights Revenue of $124.6 million, a 20.0% increase compared to third quarter 2022 Gross margin of 66.2%, a 210-basis point decline compared to third quarter 2022 Cash, cash equivalents and marketable securities of $158.5 million as of September 30, 2023 Increased fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million Recent Operational Highlights Achieved record registration volumes during the quarter and launched next generation Zio monitor with enhanced Zio service that builds upon the strong historical performance of Zio XT Opened iRhythm's Global Business Services center in the Philippines, positioning the company to maintain patient satisfaction, scale globally, and perform more efficiently mSToPs cost-effectiveness data published in Circulation: Cardiovascular Quality and Outcomes demonstrating that systematic screening for atrial fibrillation (AFib) with the iRhythm Zio XT patch provided high value from a health economic perspective Upcoming data presentations at the American Heart Association (AHA) in Philadelphia from November 11-13, 2023 "Building on momentum from the first half of 2023, our teams achieved record registration volumes in the third quarter," said Quentin Blackford, iRhythm's President and CEO.

iRhythm Technologies Announces Third Quarter 2023 Financial Results

The heavy selling pressure might have exhausted for iRhythm Technologies (IRTC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -23.87% in 4 Weeks, Here's Why iRhythm Technologies (IRTC) Looks Ripe for a Turnaround

IRhythm Technologies (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRhythm Technologies (IRTC) Expected to Beat Earnings Estimates: Should You Buy?

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2023 after the close of trading on Thursday, November 2, 2023. The company's management team will host a corresponding conference call beginning at 1:30 p.m.

iRhythm Technologies to Report Third Quarter 2023 Financial Results on November 2, 2023

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

iRhythm Technologies (IRTC) Moves 7.4% Higher: Will This Strength Last?

SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio ® monitor and enhanced Zio® long-term continuous monitoring (LTCM) service. Zio monitor is iRhythm's smallest, lightest and thinnest cardiac monitor, enhancing the cardiac monitoring experience for patients and healthcare providers together with new service enhancements.

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the Company will be participating in the upcoming Baird 2023 Global Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference.

iRhythm Technologies to Participate in Two Investor Conferences in September

Arista Networks

Aptiv Holdings Ltd

ASML Hld

CrowdStrike

Rigetti Computing

NuScale Power Corp

Although value-oriented enterprises may arguably offer a safer, more reliable route to success, few sectors are as exciting (and potentially rewarding in an accelerated sense) as the top growth stocks to buy. Fundamentally, investors gravitate toward this sector for exactly that: growth over a hopefully short period of time in exchange for accepting higher-than-average volatility risk.

Revolutionizing Tech: 7 Growth Stocks to Grab for Dynamic Returns

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Stephanie Zhadkevich - Director of Investor Relations Quentin Blackford - President and Chief Executive Officer Brice Bobzien - Chief Financial Officer Daniel Wilson - Executive Vice President of Corporate Development and Investor Relations Conference Call Participants Margaret Kaczor - William Blair Lily Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG LLC Samuel Brodovsky - Truist Securities Nathan Treybeck - Wells Fargo David Rescott - Baird David Saxon - Needham John Young - Canaccord Genuity Corp. Suraj Kalia - Oppenheimer Michael Polark - Wolfe Research Operator Hello, and welcome to today's iRhythm Technologies, Inc. Q2 2023 Earnings Conference Call. My name is Bailey, and I will be your moderator for today's call.

iRhythm Technologies, Inc. (IRTC) Q2 2023 Earnings Call Transcript

Designation reflects recommendation by the Japanese Heart Rhythm Society (JHRS) Shonin pre-market application submitted by iRhythm in July 2023 SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that its application for manufacturing and marketing approval for Zio Monitor System in Japan has been designated for high medical needs by the Japanese Ministry of Health, Labour, and Welfare (“MHLW”). The high medical needs designation in Japan is granted to innovative devices recognized as having high medical utility for significant diseases.

Zio Granted High Medical Needs Designation by the Japanese Ministry of Health, Labour, and Welfare

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and six months ended June 30, 2023.

iRhythm Technologies Announces Second Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against iRhythm Technologies, Inc. and Encourages Investors with Losses to Contact the Firm

SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2023 after the close of trading on Thursday, August 3, 2023. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report Second Quarter 2023 Financial Results on August 3, 2023

Zio XT value proposition lives up to its claims and demonstrates high value around clinical utility and payer economics Zio XT value proposition lives up to its claims and demonstrates high value around clinical utility and payer economics

NAMCP Independent Third-Party Review Validates Value Proposition of iRhythm Zio XT Service to Health Systems and Payers

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of iRhythm Technologies, Inc. ("iRhythm" or the "Company") (NASDAQ: IRTC). Such investors are advised to contact Robert S.

News for iRhythm Technologies Stock (IRTC)